Filed under: Deals, Shareholders, Value and lack thereof, Public or private?

Invitrogen Corp. (NASDAQ: IVGN) has announced a $6.7 billion cash and stock acquisition for Applera’s Applied Biosystems Group (NYSE: ABI). The breakdown is 45% percent in cash and 55% in stock.

Invitrogen Corp. will pay $38.00 per share between the cash and stock, compared to yesterday’s close of $32.44 and compared to the $37.67 52-week high. After the deal closes, it sees fiscal and calendar year 2009 organic revenue growth in the mid-single digits.

The company says that the combined operations will have annual sales of $3.5 billion and is expected to be neutral to slightly accretive to Invitrogen’s earnings per share the first year after close and significantly accretive in year two.

Continue reading the terms and condition implications at BioHealthInvestor.com.

Share This

Share This

This entry was posted on Thursday, June 12th, 2008 at 8:26 am and is filed under Engagements and Deals News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.